Price (1/16/2007): 4.43 Price (5/4/2007): 19.39 Gain during game: 14.96 (337%) Price (6/4/2007): 8.2 Gain/Loss from 5/4/2007: -11.19 (-57.71%) Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Provenge - drug for advanced prostate cancer. June 6, 2007 - DNDN taps financing sooner than expected.. Shares of Dendreon (DNDN) are trading down some 7% pre-market after the company announced that it was going to offer $75 million in convertible senior subordinated notes that are due in 2014. The offering is being made under Rule 144A to qualified institutional buyers, so the securities will not be required to be registered until a reseale period. In other words, DNDN is burning cash. Not a good sign. Jim Cramer - May 14, 2007 - There's no substantive reason DNDN will bounce back. It needs more financing. John Markman - Phase 1 and Phase 2 trials didn't use as manhy patients as most drug analysts would like to see. DNDN at 3 at end of March. Panel made recommendation, so stock went to 20 in 3 days. But how much influence did FDA panel have on final decision? Better trial on Provenge, but result won't be available in 2008. FDA wants to wait. He recommends: play the volatility, options straddle 100% up 80% down. Close out losing side immediately.

Price (1/16/2007): 2.6 Price (5/4/2007): 8.68 Gain during game: 6.08 (233%) Price (6/4/2007): 7.23 Gain/Loss from 5/4/2007: -1.45 (-16.71%) March 20, 2007 - Wallstrip video - 2005 Energy Act gave 50% tax credit for installing solar panels. Gave boost to stocks like ASTI and TSL. When will it affect (if it affects at all) the price of the stock? March 14, 2007 - Ascent Solar Technologies (Nasdaq: ASTI) 41% HIGHER; announced Norsk Hydro ASA (NYSE: NHY) acquired 1.6 million shares of the common stock of Ascent in a private placement as the precursor to a strategic relationship between the parties.

Price (1/16/2007): 19.1 Price (5/4/2007): 56.41 Gain during game: 37.31 (195%) Price (6/4/2007): 42.75 Gain/Loss from 5/4/2007: -13.66 (-24.22%) March 20, 2007 - Wallstrip video - 2005 Energy Act gave 50% tax credit for installing solar panels. Gave boost to stocks like ASTI and TSL. When will it affect (if it affects at all) the price of the stock? June 1, 2007 - Add-on offering of 5.4 million shares of ADSs at $45/share. May 21, 2007 - Trina Solar's net revenues in the first quarter of 2007 were $42.5 million, an increase of 9.8% sequentially and 194.4% year-over-year. Total shipments increased to 10.52 MW, up from 8.98 MW in the fourth quarter of 2006 and 3.34 MW in the first quarter of 2006. Average sales price ("ASP") was $3.80 in the first quarter of 2007, compared to $3.86 in the fourth quarter of 2006, and $4.03 in the first quarter of 2006. Sales to customers in Europe continued to generate almost all of the total net revenues in the first quarter of 2007.

Price (1/16/2007): 9.59 Price (5/4/2007): 24.76 Gain during game: 15.17 (158%) Price (6/4/2007): 16.52 Gain/Loss from 5/4/2007: -8.24 (-33.28%) Kreisler Manufacturing manufactures precision metal components and assemblies primarily for use in military and commercial aircraft engines and in industrial gas turbine engines. Products include tube assemblies of multiple sizes and configurations, vane inserts, fuel rings and baffles. Marketwatch article February 14, 2007 - KRSL shares jumped 26% to $14 in Wednesday morning trade after the Elmwood Park, N.J.-based maker of metal components and assemblies reported fiscal second-quarter net earnings of $607,000, or 33 cents a share, up from $289,794, or 16 cents a share last year. Revenue rose to $6.02 million from $4.43 million May 15, 2007 - KRSL shares slid 15% to 19.35 after 3rd quarter net profit slid from $.24/share to $.18/share.

Price (1/16/2007): 3.84 Price (5/4/2007): 9 Gain during game: 5.16 (134%) Price (6/4/2007): 9.49 Gain/Loss from 5/4/2007: 0.49 (5.44%) Vicon Industries, Inc. engages in the design, manufacture, assembly, and marketing of a range of video systems and system components used for security, surveillance, safety, and control purposes by various end users. Based in Hauppauge, LI, NY. Quarterly revenue growth: 38% Price/Sales ratio: .70 1st quarter profit up 700% from a year ago - Long Island Business News February 6, 2007 Vicon Industries Inc. on Tuesday posted a first quarter profit almost 700 percent higher than the year ago quarter, fueled mostly by a boon in its foreign sales. AS a result, its stock price nearly doubled. The Hauppauge-based firm, for the quarter ended Dec. 31, posted net income of $1.1 million, up from $147,000 in the same period last year. On a per-share basis, profit was 24 cents per share, compared to 3 cents per share in the prior-year period. Shares of Vicon (AMEX: VII) ballooned by $2.85, more than 71 percent, to trade at $6.63 per share, a new 52-week high by nearly $3. Sales for the quarter were $17.9 million, up 25 percent from $14.3 million last year. U.S. sales gained 32 percent to $9.7 million ad foreign sales gained 19 percent to hit $8.2 million. Vicon said its digital surveillance products accounted for 34 percent of its revenue. Operating costs jumped to $573,000 based on its increased investment in product development.

Price (1/16/2007): 12.4 Price (5/4/2007): 28.04 Gain: 15.64 (126%) Price (6/4/2007): 33.52 Gain/Loss from 5/4/2007: 5.48 (19.54%) Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that target the molecular mechanisms implicated in cancer in the United States. Mid February, 2007 - good news on Nexavar, a kidney cancer drug, that appears to work with kidney cancer as well, caused price to jump. Bayer partnering with ONXX. Could be a candidate for Bayer to take ONXX out. Adam Feuerstein wrote on the action. Jumped from 12 to 25 in med-Feb. Feuerstein thinks it could go to 40. Options strategy, March 8, 2007, from Steve Smith, on ONXX. Buy at the money calls at August, 2007.

Price (1/16/2007): 12.4 Price (5/4/2007): 28.04 Gain: 15.64 (126%) Price (6/4/2007): 33.52 Gain/Loss from 5/4/2007: 5.48 (19.54%) Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that target the molecular mechanisms implicated in cancer in the United States. Mid February, 2007 - good news on Nexavar, a kidney cancer drug, that appears to work with kidney cancer as well, caused price to jump. Bayer partnering with ONXX. Could be a candidate for Bayer to take ONXX out. Adam Feuerstein wrote on the action. Jumped from 12 to 25 in med-Feb. Feuerstein thinks it could go to 40. Options strategy, March 8, 2007, from Steve Smith, on ONXX. Buy at the money calls at August, 2007.

Price (1/16/2007): 3.03 Price (5/4/2007): 6.8 Gain: 3.77 (124%) Price (6/4/2007): 6.13 Gain/Loss from 5/4/2007: -0.67 (-9.85%) Produces quality frozen food products including entrees, plated meals, meal components, soups, sauces, poultry, meat and fish specialties. This value-added manufacturer provides custom prepared foods to a number of prominent customers, such as Panda Restaurant Group, Inc. and Jenny Craig, Inc. OFI signs 3 year agreement with national food brand. I've-been-holding-this-little-shit-for-months-and-nothing-and-now-that-I-sell-the-fucker-the-stock-soars micro-cap stock was Overhill Farms, Inc. (AMEX: OFI). The stock jumped nearly 47% today after the company signed a three-year agreement to produce meals for a major national food brand. The agreement is expected to generate sales of approximately $43 million during the first year. The company said it is on track to reach annual revenues of over $200M by Q3, versus the $168.3M reported all of last year. This one could have legs.